As of 2026-03-24, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 75.05 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 11.2x | 8.7x |
| Forward P/E multiples | 7.9x - 16.8x | 12.0x |
| Fair Price | (3.28) - (4.54) | (4.23) |
| Upside | -105826.4% - -146507.6% | -136401.7% |
| Date | EV/EBITDA |
| 2026-03-20 | -0.22 |
| 2026-03-19 | -0.22 |
| 2026-03-18 | -0.22 |
| 2026-03-17 | -0.22 |
| 2026-03-16 | -0.22 |
| 2026-03-13 | -0.22 |
| 2026-03-12 | -0.22 |
| 2026-03-11 | -0.22 |
| 2026-03-10 | -0.22 |
| 2026-03-09 | -0.22 |
| 2026-03-06 | -0.22 |
| 2026-03-05 | -0.22 |
| 2026-03-04 | -0.22 |
| 2026-03-03 | -0.22 |
| 2026-03-02 | -0.22 |
| 2026-02-27 | -0.22 |
| 2026-02-26 | -0.22 |
| 2026-02-25 | -0.22 |
| 2026-02-24 | -0.22 |
| 2026-02-23 | -0.22 |
| 2026-02-20 | -0.22 |
| 2026-02-19 | -0.22 |
| 2026-02-18 | -0.22 |
| 2026-02-17 | -0.22 |
| 2026-02-13 | -0.22 |
| 2026-02-12 | -0.22 |
| 2026-02-11 | -0.22 |
| 2026-02-10 | -0.22 |
| 2026-02-09 | -0.22 |
| 2026-02-06 | -0.22 |
| 2026-02-05 | -0.22 |
| 2026-02-04 | -0.22 |
| 2026-02-03 | -0.22 |
| 2026-02-02 | -0.22 |
| 2026-01-30 | -0.22 |
| 2026-01-29 | -0.22 |
| 2026-01-28 | -0.22 |
| 2026-01-27 | -0.22 |
| 2026-01-26 | -0.22 |
| 2026-01-23 | -0.22 |
| 2026-01-22 | -0.22 |
| 2026-01-21 | -0.22 |
| 2026-01-20 | -0.22 |
| 2026-01-16 | -0.22 |
| 2026-01-15 | -0.22 |
| 2026-01-14 | -0.22 |
| 2026-01-13 | -0.22 |
| 2026-01-12 | -0.22 |
| 2026-01-09 | -0.22 |
| 2026-01-08 | -0.22 |